Autopsy report · NCT02355431

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study withdrawn before enrolling first patient”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: Incyte Corporation
Sponsor type: Industry
Conditions: Solid Tumors and Hematologic Malignancy; NSCLC (Non-small Cell Lung Carcinoma)
Interventions: Itacitinib; erlotinib; placebo
Participants: 0
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.